What is QuikClot®?
Innovation in hemostasis

QuikClot® hemostatic devices are different from standard surgical gauzes and other hemostatic agents. They stop bleeding significantly faster and are more effective than standard gauzes1,2—and they are just as safe and intuitive to use.11


Unlike other hemostatics, QuikClot® devices are impregnated with kaolin, an inorganic mineral that accelerates the body’s natural clotting ability1,4 and produces no exothermic reaction. You or your team can achieve hemostasis confidently—without worry of instigating an allergic response.1,4


QuikClot® devices do not contain:

  • Animal proteins
  • Human proteins
  • Shellfish
  • Botanicals

QuikClot® hemostatic devices for a range of uses

Trauma is a major cause of death and disability and the second most expensive healthcare problem in the United States. Approximately 40% of trauma-related deaths are due to bleeding or its consequences, establishing hemorrage as the most common cause of preventable death in trauma.9


QuikClot® devices, applied with manual pressure, promote clotting within minutes from application to help you and your team save more lives.


QuikClot® devices come in many different forms and sizes, which are adaptable to treat a broad range of bleeding situations. They are trusted and relied on by: 


QuikClot® hemostatic devices at a glance:

Fast & Effective

  • Promotes clotting within minutes of application 1-3,5,11
  • The Committee on Tactical Combat Casualty Care (CoTCCC) recommends QuikClot Combat Gauze® as the hemostatic agent of choice for compressible hemorrhage not amenable to tourniquet use.6



  • No shellfish, human, or animal proteins
  • Low-to-no risk of adverse reactions8



  • Familiar and easy-to-use format
  • Conforms readily to wound site


Efficient & Valuable

  • Less expensive than protein-based products; may reduce the need for additional expensive treatments4
  • Stops bleeding faster than standard gauze1,2


View Products


QuikClot® kaolin technology accelerates the body’s natural clotting cascade2

For more than 8 years, QuikClot® hemostatic devices have been made with kaolin.  Kaolin works on contact with blood to immediately initiate the clotting process by activating factor XII.4 This reaction leads to the transformation of factor XII to its activated form XIIa, which instigates the rest of the coagulation cascade.13



QuikClot® hemostatic devices promote clotting within minutes1-3,5,11

Rotational Thromboelastometry (ROTEM) is used in bleeding situations to assess the viscoelastic properties of whole blood hemostasis.  In vitro, ROTEM demonstrates the kinetics of clot formation associated with the interaction of enzymatic coagulation factors, fibrinogen, platelets and cellular components and is a recommended diagnostic tool for assessment and guidance when controlling bleeding.  Clot Time (CT) describes the onset of clot formation (in sec), Clot Formation Time (CFT) shows clot propagation (in sec), and the alpha angle (α) is taken tangent to the clotting curve at 2mm (in degrees ᵒ). 

QuikClot treated blood shows a faster CT, shorter CFT and steeper α than blood alone which indicates that the clot is activated quickly and amplifies rapidly.  The greater the amplitude of the graph, the firmer the clot (A10, MCF: maximum clot firmness).  As can be seen in the graph, QuikClot treated blood forms a firmer clot faster than untreated blood. 


QuikClot Combat Gauze® is recommended by CoTCCC for all 5 branches of the US military6

In 2008, after extensive testing, the CoTCCC chose QuikClot Combat Gauze® as the only hemostatic dressing used by all branches of the US military for compressible hemorrhage not amenable to tourniquet use or as an adjunct to tourniquet removal if evacuation time is anticipated to be longer than 2 hours.6 Today, QuikClot Combat Gauze® still remains the hemostatic device of choice by the CoTCCC. The Department of Defense is funding research to explore other applications of QuikClot® products in bleeding associated with traumatic injuries. QuikClot® dressings are credited with saving lives.



Read the test results published in the journal of trauma


QuikClot®: Our history of success

QuikClot® hemostatic devices deliver the kind of innovation you can expect from Z-Medica®.

Show TimelineHide Timeline
  •  2002
    • Novel hemostatic agent discovered–original Generation 1 product developed
    • Z-Medica Corporation founded
  •  2002-present
    • US military begins using and continues to use QuikClot® products
  •  2005
    • Second-generation “bean bag” products ACS+ and 1st Response are introduced
  •  2006
    • Third-generation kaolin-based hemostatic agent is developed
  •  2008
    • QuikClot Combat Gauze® introduced
    • QuikClot Combat Gauze® becomes the only hemostatic dressing recommended by CoTCCC for US military use for compressible hemorrhage not amenable to tourniquet use or as an adjunct to tourniquet removal if evacuation time is anticipated to be longer than 2 hours6
  •  2009
    • QuikClot® InterventionalTM is released
  •  2013
    • Topical surgical wound/traumatic bleeding clearance granted by FDA
    • QuikClot® InterventionalTM cleared for drug-induced, anticoagulated patients 
  •  2014
    • CoTCCC reaffirms QuikClot Combat Gauze® as the hemostatic dressing of choice for compressible hemorrhage not amenable to tourniquet use 
  Hide TimelineShow Timeline


Watch how QuikClot® kaolin technology accelerates the clotting process.

View Now

Open AllClose All
  Show References

References: 1. Trabattoni D, Montorsi P, Fabbiocchi F, Lualdi A, Gatto P, Bartorelli A. A new kaolin-based haemostatic bandage compared with manual compression for bleeding control after percutaneous coronary procedures. Eur Radiol. 2011;21:1687-1691. 2. Politi L, Aprile A, Paganelli C, et al. Randomized clinical trial on short-time compression with kaolin-filled pad: a new strategy to avoid early bleeding and subacute radial artery occlusion after percutaneous coronary intervention. J Interven Cardiol. 2011;24:65-72. 3. Trabattoni D, Gatto P, Bartorelli A. A new kaolin-based hemostatic bandage use after coronary diagnostic and interventional procedures. Int J Cardiol. 2012;156(1):53-54. 4. Lamb KM, Pitcher HT, Cavarocchi NC, Hirose H. Vascular site hemostasis in percutaneous extracorporeal membrane oxygenation therapy. Open Cardiovasc Thorac Surg J. 2012;5:8-10. 5. Pahari M, Moliver R, Lo D, Pinkerton D, Basadonna G. QuikClot® Interventional™ Hemostatic Bandage (QCI): a novel hemostatic agent for vascular access. Cath Lab Digest. 2010;18(1):28-30. http://www.cathlabdigest.com/articles/QuikClot®-Interventional™-Hemostatic-Bandage-QCI-A-Novel-Hemostatic-Agent-Vascular-Access. Accessed on August 10, 2014. 6. Tactical Combat Casualty Care Guidelines 2 June 2014. http://www.usaisr.amedd.army.mil/pdfs/TCCC_Guidelines_140602.pdf. Accessed March 25, 2015. 7. Margolis J. Initiation of blood coagulation by glass and related surfaces. Journal Physiol 1957;137:95-109. 8. Data on file. 9. Curry N, Hopewell S, Doree C, Hyde C, Brohi K, Stanworth S. The acute management of trauma hemorrhage: a systematic review of randomized controlled trials. Crit Care. 2011;15(2):R92. 10. Kheirabadi BS, Mace JE, Terrazas IB, et al. Safetry evaluation of new hemostatic agents, smectite granules, and kaolin covered gauze in vascular injury wound model in swine. J Trauma. 2010;68:269-278. 11. Kheirabadi BS, Scherer MR, Estep JS, Dubick MA, Holcomb JB. Determination of efficacy of new hemostatic dressing in a model of extremity arterial hemorrhage in swine. J Trauma. 2009;67:450-460. 12. Kheirabadi BS. Evaluation of topical hemostatic agents for combat wound treatment. US Army Med Dep J. 2011;25-37. 13. Dee KC, Puleo DA, Bizios R. Tissue-Biomaterial Interactions. Hoboken: Wiley & Sons, 2002. 14. Data compiled from multiple sources and on file. 15. Blair, J. Pete, and Schweit, Katherine W. (2014). A Study of Active Shooter Incidents, 2000 - 2013. Texas State University and Federal Bureau of Investigation, US Department of Justice, Washington D.C. 2014. 16. Kauvar DS, Lefering R, Wade CE. Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations. J Trauma. 2006; 60:S3-S11. 17. Zietlow JM, Zietlow SP, Morris DS, Berns KS, Jenkins DH. Prehospital Use of Hemostatic Bandages and Tourniquets: Translation From Military Experience to Implementation in Civilian Trauma Care. J Spec Oper Med. 2015 Summer;15(2):48-53. 18. Schauer SG, April MD, Naylor JF, Fisher AD, Cunningham CW, Ryan KL, Thomas KC, Brillhart DB, Fernandez JRD, Antonacci MA. QuikClot Combat Gauze® Use by Ground Forces in Afghanistan The Prehospital Trauma Registry Experience. J Spec Oper Med. Summer 2017;17(2):101-106. 19. Shina A1, Lipsky AM, Nadler R, Levi M, Benov A, Ran Y, Yitzhak A, Glassberg E. Prehospital use of hemostatic dressings by the Israel Defense Forces Medical Corps: A case series of 122 patients. J Trauma Acute Care Surg. 2015 Oct;79 (4 Suppl 2):S204-9. 20. Boulton AJ, Lewis CT, Naumann DN, Midwinter MJ. Prehospital haemostatic dressings for trauma: a systematic review. Emerg Med J. 2018; 35: 449-457.

Our site includes links to third party sites in which the Z-Medica® Privacy Policy and Terms of Use do not apply. Please read the privacy policy for every third party website you visit.

Close Continue Close


We have placed cookies on your computer to give you the best possible experience with our website. These cookies are also used to ensure we show you advertising that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time.
Privacy Policy